WALTHAM, Mass.--(BUSINESS WIRE)--Innoviva Specialty Therapeutics (IST), a subsidiary of Innoviva, In

Cantor Fitzgerald analyst Steve Seedhouse maintains Innoviva (NASDAQ:INVA) with a Overweight and

Innoviva is a company that is transitioning from a pure royalty-based business to a diversified heal

Innoviva (INVA) came out with quarterly earnings of $0.59 per share, beating the Zacks Consensus Est

Innoviva (NASDAQ:INVA) reported quarterly losses of $(1.14) per share which missed the analyst conse

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a

Supernus Pharmaceuticals NASDAQ: SUPN and Indivior Pharmaceuticals announced a proposed all-stock, t

Dimensional Fund Advisors LP grew its holdings in shares of Innoviva, Inc. (NASDAQ: INVA) by 1.7% in

Nortiva Bio, Inc. (“Nortiva”) today announced its launch as a clinical-stage biopharmaceutical c

Company is advancing its proprietary LYNX™ drug delivery platform to develop oral therapies that las

LEXINGTON, Mass.--(BUSINESS WIRE)--Nortiva Bio, Inc. (“Nortiva”) today announced its launch as a cli

Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. (Nasdaq: INVA), today announced that

WALTHAM, Mass.--(BUSINESS WIRE)--Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. (Na

Innoviva, Inc. (INVA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transc

Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified biopharmaceutical

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Innoviva (NASDAQ:INVA) with a Buy a

Innoviva develops respiratory pharmaceuticals through strategic partnerships and royalty agreements

BTIG analyst Julian Harrison maintains Innoviva (NASDAQ:INVA) with a Buy and raises the price tar

Innoviva (INVA) came out with quarterly earnings of $0.44 per share, beating the Zacks Consensus Est

Innoviva (NASDAQ:INVA) reported quarterly earnings of $2.22 per share which beat the analyst consens

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a

Merck (MRK) came out with a quarterly loss of $1.28 per share versus the Zacks Consensus Estimate of

Shares of Innoviva, Inc. (NASDAQ: INVA - Get Free Report) have been assigned a consensus rating of "

The price-to-earnings (P/E) ratio is a commonly used metric that provides a snapshot of a company's

Innoviva, Inc. (NASDAQ: INVA - Get Free Report)'s stock price passed above its two hundred day movin

Shares of Innoviva, Inc. (NASDAQ: INVA - Get Free Report) have earned a consensus rating of "Moderat

  On Friday, 497 companies set new 52-week lows.

  On Wednesday, 100 stocks hit new 52-week lows.

  On Thursday, 1076 companies hit new 52-week lows.

  On Tuesday, 507 stocks hit new 52-week lows.

  During Friday's session, 574 stocks hit new 52-week lows.

  On Tuesday, 126 companies set new 52-week lows.

  On Friday, 122 stocks hit new 52-week lows.

  On Thursday, 529 companies set new 52-week lows.

  On Monday, 273 companies set new 52-week lows.

  During Friday's session, 132 stocks hit new 52-week lows.

  On Thursday, 108 companies set new 52-week lows.

Upgrades

    Before 10 a.m. ET on Wednesday, 77 companies hit new 52-week highs.

    During Friday's morning session, 137 companies made new 52-week highs.

    On Thursday morning, 159 companies achieved new highs for the year.

    Before 10 a.m. ET Wednesday, 138 stocks hit new 52-week highs.

    During Tuesday's morning trading, 101 companies set new 52-week highs.

    Before 10 a.m. ET on Monday, 201 companies set new 52-week highs.

  Thursday's morning session saw 167 companies set new 52-week highs.